Global congenital heart diseases market size reached $4.2 billion in 2025 and is projected to expand to $7.9 billion by 2035, growing at a CAGR of 6.7% during the forecast period (2026–2035). Market growth is supported by rising birth prevalence of cardiac defects, improvements in diagnostic imaging, and expanding access to pediatric cardiac care.
Browse the full report description of “Congenital Heart Diseases Market, By Defect Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, By Diagnosis (Echocardiogram, Chest X-ray, MRI, and Others), By Treatment (Medications, Implantable Heart Device, Catheter Procedure, Open Heart Surgery, and Heart Transplant), End-Users (Hospitals and Clinics, Diagnostic Centers, Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/congenital-heart-diseases-market
Key Market Drivers
Regional Analysis
Asia-Pacific is expected to witness growth due to large birth cohorts and improving healthcare infrastructure across countries such as India and China. In India, government programs targeting maternal and child health, along with expanding pediatric cardiac surgery capabilities in public hospitals, are increasing diagnosis and treatment rates. China continues to invest in tertiary hospitals and medical technology adoption, improving early detection through prenatal screening initiatives. Rising awareness and insurance coverage expansion in urban areas further contribute to market demand across the region.
North America remains a significant market driven by advanced healthcare systems and high diagnostic penetration. The US benefits from established pediatric cardiology networks, newborn screening protocols, and reimbursement frameworks supporting surgical and interventional procedures. Ongoing clinical research and widespread availability of sophisticated imaging modalities such as fetal echocardiography support early detection and treatment planning. Long-term care needs among adults living with repaired congenital heart defects also contribute to sustained demand for medications, implantable devices, and follow-up interventions.
Europe shows stable growth supported by universal healthcare coverage and coordinated congenital heart disease registries across multiple countries. Regional policies emphasize early screening, standardized treatment pathways, and cross-border collaboration for complex surgical cases. Western European countries maintain strong pediatric cardiac care infrastructure, while Central and Eastern Europe are expanding specialized centers with support from national health programs. Increased survival into adulthood has created a growing population requiring ongoing monitoring and secondary interventions.
Competitive Landscape
Key companies operating in the global congenital heart diseases market include Boston Scientific Corp., Johnson & Johnson, Pfizer Inc., Sanofi S.A., and Thermo Fisher Scientific Inc., among others. These companies provide a range of products including diagnostic imaging systems, implantable cardiac devices etc.
Recent Market Developments
Market Coverage
Competitive Landscape- Boston Scientific Corp., Johnson & Johnson, Pfizer Inc., Sanofi S.A., and Thermo Fisher Scientific Inc., among others.
Key questions addressed by the report.
Global Congenital Heart Diseases Market Report Segment
By defect type
By diagnosis
By treatment
By end user
Global Congenital Heart Diseases Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/congenital-heart-diseases-market